Valneva SE (VALN) Cash from Investing Activities (2021 - 2026)

Valneva SE (VALN) posted quarterly Cash from Investing Activities of $312937.4 for Q1 2026, up 128.62% year-on-year from $136883.4 in Q1 2025, and up 204.17% on a QoQ basis from -$300419.9 in Q4 2025.

Valneva SE (VALN) Cash from Investing Activities (2021 - 2026) Analysis & Trends

Valneva SE (VALN) has reported Cash from Investing Activities for 6 consecutive years, with $312937.4 the latest figure, recorded in Q1 2026.

  • Quarterly Cash from Investing Activities rose 128.62% year-over-year to $312937.4 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$538252.4 (up 95.6% YoY) and the FY2025 annual result came in at -$1.9 million, down 102.22% from the prior year.
  • Cash from Investing Activities grew to $312937.4 in Q1 2026 per VALN's latest filing, from -$300419.9 in the prior quarter.
  • Over the last five years, Cash from Investing Activities for VALN reached as high as $7.5 billion in Q3 2023 and fell as low as -$7.5 billion in Q2 2023.
  • A 5-year average of $1.7 million and a median of -$1.1 million in 2025 frame the typical range for Cash from Investing Activities.
  • The largest YoY upside for Cash from Investing Activities was 102222.53% in 2023 against a maximum downside of 101128.64% in 2023.
  • Year by year, Cash from Investing Activities stood at -$7.5 million in 2022, then slumped by 148.3% to -$18.6 million in 2023, then surged by 128.73% to $5.3 million in 2024, then plunged by 105.63% to -$300419.9 in 2025, then surged by 204.17% to $312937.4 in 2026.
  • According to Business Quant data, Cash from Investing Activities over the past three periods registered $312937.4, -$300419.9, and $224177.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Oculis Holding AG 67,042.03 Bn 67,041.74 Bn - -
2 Nanobiotix 1,911.83 Bn 1,911.77 Bn - -
3 Akari Therapeutics 989.71 Bn 989.71 Bn - -
4 BeOne Medicines 471.62 Bn 466.83 Bn 1.35 Bn -45.51 Mn
5 Vertex Pharmaceuticals 121.97 Bn 114.72 Bn 2.59 Bn -431.90 Mn
6 Regeneron Pharmaceuticals 69.98 Bn 61.22 Bn 3.31 Bn -428.90 Mn
7 Belite Bio 62.68 Bn 62.68 Bn - -
8 Argenx Se 55.75 Bn 50.57 Bn 1.41 Bn -
9 Alnylam Pharmaceuticals 37.49 Bn 34.48 Bn 959.66 Mn -25.54 Mn
10 Valneva SE 839.18 Mn 719.39 Mn 5.38 Mn 312,937.42

Historic Data

Download Data
DateValue
Mar 31, 2026 312,937.42
Mar 31, 2026 312,937.42
Dec 31, 2025 -300,419.93
Dec 31, 2025 -300,419.93
Sep 30, 2025 224,176.99
Sep 30, 2025 224,176.99
Jun 30, 2025 -774,946.86
Jun 30, 2025 -774,946.86
Mar 31, 2025 -1.09 Mn
Mar 31, 2025 -1.09 Mn
Dec 31, 2024 5.33 Mn
Dec 31, 2024 5.33 Mn
Sep 30, 2024 -17.50 Mn
Sep 30, 2024 -17.50 Mn
Jun 30, 2024 1.02 Mn
Jun 30, 2024 1.02 Mn
Mar 31, 2024 98.68 Mn
Mar 31, 2024 98.68 Mn
Dec 31, 2023 -18.57 Mn
Dec 31, 2023 -18.57 Mn